Keros Therapeutics (KROS)

Executive Summary

Keros Therapeutics is a clinical-stage biopharmaceutical company pioneering novel therapies targeting the TGF-β signaling pathway to address unmet needs in hematologic, pulmonary, and cardiovascular disorders. Its lead programs include KER-012, a ligand trap for activin and myostatin, which recently completed a Phase 2 trial in pulmonary arterial hypertension (PAH) with topline data expected soon, and KER-047, an activin receptor-like kinase-2 inhibitor for iron deficiency anemia, though its Phase 2 study was withdrawn. The company also has preclinical candidates in earlier stages. With a strong scientific foundation and a focused pipeline, Keros is poised to deliver pivotal data that could validate its platform and drive value.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 topline data for KER-012 in pulmonary arterial hypertension45% success
• Q1 2027Initiation of Phase 3 study for KER-012 in PAH30% success
• Q4 2026Preclinical data update for early-stage pipeline candidates60% success